Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Patients With IgG4-Related Disease
NCT04602598Phase 2Completed
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in IgG4-related disease (IgG4-RD). Primary endpoints: Volume of the Submandibular Glands on PET-MRI at 24 weeks and Volume of the Lacrimal Glands on PET-MRI at 24 weeks. Started Aug 2022; status: completed.
02
Drugs
zanubrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT04602598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602598.